Alzheimer's disease (AD) is currently defined at the research level by the aggregation of
amyloid-β (Aβ) and tau proteins in brain. While biofluid biomarkers are available to measure …

Alzheimer's disease (AD) is currently defined by the aggregation of amyloid-β (Aβ) and tau
proteins in the brain. Although biofluid biomarkers are available to measure Aβ and tau …

Alzheimer's disease (AD) features a complex web of pathological processes beyond
amyloid accumulation and tau-mediated neuronal death. To meaningfully advance AD …

Abstract Changes in Amyloid-β (A), hyperphosphorylated Tau (T) in brain and cerebrospinal
fluid (CSF) precedes AD symptoms, making CSF proteome a potential avenue to understand …

Robust and accessible biomarkers that can capture the heterogeneity of Alzheimer's
disease and its diverse pathological processes are urgently needed. Here, we undertook an …

Alzheimer's disease (AD) is the most common form of dementia, with cerebrospinal fluid
(CSF) β-amyloid (Aβ), total Tau, and phosphorylated Tau providing the most sensitive and …

Alzheimer's disease (AD) is an irreversible neurodegenerative disease characterized by
progressive cognitive decline. The two cardinal neuropathological hallmarks of AD include …

Heterogeneity in progression to Alzheimer's disease (AD) poses challenges for both clinical
prognosis and clinical trial implementation. Multiple AD-related subtypes have previously …

Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …